L1CAM in human cancer

• Verfasst von: Altevogt, Peter [VerfasserIn]
• Verfasst von: Doberstein, Kai [VerfasserIn]
• Verfasst von: Fogel, Mina [VerfasserIn]
• Titel: L1CAM in human cancer
• Verf.angabe: Peter Altevogt, Kai Doberstein and Mina Fogel
• Jahr: 2016
• Jahr des Originals: 2015
• Umfang: 12 S.
• Fussnoten: Gesehen am 28.03.2019 ; Online 24 June 2015
• Titel Quelle: Enthalten in: International journal of cancer
• Ort Quelle: Bognor Regis : Wiley-Liss, 1966
• Jahr Quelle: 2016
• Band/Heft Quelle: 138(2016), 7, Seite 1565-1576
• ISSN Quelle: 1097-0215
• DOI: doi:10.1002/ijc.29658
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: immunohistochemistry
• Sach-SW: L1CAM
• Sach-SW: therapy model
• Sach-SW: tumor therapy
• K10plus-PPN: 1662521669

Abstract

L1 cell adhesion molecule (L1CAM) is one of the first neural adhesion molecules described with important functions in the development of the nervous system. Subsequent work discovered that L1CAM is expressed in many human cancers and is often associated with bad prognosis. This is most likely due to the motility and invasion promoting function of L1CAM. Here, we describe the path L1CAM has taken from a neural adhesion molecule to a recognized tumor antigen. We summarize the literature on L1CAM expression in cancers and pre-cancerous lesions. We focus on the genetic elements required for its re-expression and highlight preclinical studies for targeted therapy. The data suggest that L1CAM is a valuable diagnostic/prognostic marker and an attractive target for the therapy of several human cancers.